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Editorial
Steroids: Modulators of inﬂammation and immunity
The study of steroids started in the ﬁrst half of the last century.
Following the discoveries of sex steroids and then glucocorticoids
between the 1920s and 1940s, they rapidly made their way into
the clinic. From the beginning, glucocorticoids proved themselves
to be potent anti-inﬂammatory agents and they remain the most
effective therapy for many allergic and chronic inﬂammatory dis-
eases, although their use, especially at high pharmacological dose,
is limited by their diverse side effects. Endogenous steroids are
important modulators of the immune system. It is well known that
men andwomen differ in their immunity, withwomen beingmore
susceptible to auto-immune disease, but less susceptible to infec-
tions. Sex steroids modulate immunity and inﬂammation – some
of these effects may be indirect, but the presence of oestrogen and
androgen receptors within immune cells highlights the important
and direct effects they have. Recently, the involvement of other
steroids in immunity has attracted attention, in particular the role
of noncalcemic actions of vitamin D in immune cells (especially T
cells), and there is considerable promise in the use of vitamin D
to treat some allergic diseases. Some immunomodulatory steroids,
the prime example being dehydroepiandrosterone (DHEA) and its
sulfated form, DHEAS, do not even bind to members of the nuclear
receptor family. The exact mechanism how DHEA exerts its effects
still remains unknown.
This special issue of the Journal of Steroid Biochemistry and
Molecular Biology highlights the effects of these steroids upon
inﬂammation and immunity. Inﬂammation is, of course, a normal
process, being a host defence mechanism activated in response to
injury or infection that serves to control and eliminate invading
pathogens and promote the repair of damaged tissues. Many nor-
mal body processes harness aspects of the inﬂammatory response,
a prime example of this being the female reproductive system,
with its cycles of tissue damage and repair - follicular rup-
ture and release of the oocyte from the ovary, shedding of the
endometrium at menstruation with subsequent repair and regen-
eration ready for the next cycle. It is when the inﬂammatory
responsegoes awryor the initial stimuluspersists thatproblemsset
in and chronic inﬂammation ensues. Administered therapeutically,
glucocorticoids are immuno-suppressive and anti-inﬂammatory
and are widely used to control chronic inﬂammatory diseases
such as asthma, rheumatoid arthritis and dermatitis. Endoge-
nous glucocorticoids are immunomodulatory rather than simply
immunosuppressive (some of their actions can be considered
pro-inﬂammatory) and exert their effects through two members
of the nuclear receptor superfamily. Under some circumstances
the mineralocorticoid receptor (MR) acts as a high afﬁnity glu-
cocorticoid receptor, and may be responsible for some of the
pro-inﬂammatory effects of glucocorticoids, particularlywithin the
vasculature. However,most glucocorticoid actions aremediated by
the glucocorticoid receptor (GR) which is expressed almost ubiq-
uitously, including in immune cells. Its mechanism of action has
been extensively investigated, although exactly how and where
it exerts its anti-inﬂammatory effects in vivo remains the sub-
ject of some debate. In the ﬁrst paper in this volume, Baschant
and Tuckermann describe the use of conditional GR knock-out and
GR function-selective mouse models to elucidate the cell-speciﬁc
roles of GR in modulating inﬂammation and immunity. A major
clinical problem is glucocorticoid resistance, whereby patients are
(or become) non-responsive to glucocorticoids. Understanding the
cellular mechanisms that give rise to glucocorticoid resistance is
key to improving therapy. These mechanisms are reviewed in the
paper from Barnes, together with potential treatments to reverse
or by-pass glucocorticoid resistance. A key target in the develop-
ment of glucocorticoid resistance may be regulatory T cells (Treg
cells). RegulatoryT cells are critical tomaintain “tolerance” andpre-
vent inappropriate immune activation in response to ubiquitous
non-harmful allergens. Induction of regulatory T cells in patients
may be an effective therapy to treat allergic disease, especially in
glucocorticoid resistant patients. The inﬂuences of steroids on reg-
ulatory T cell induction and function is discussed by Dimeloe et
al. This is followed by a paper from De Bosscher who describes
the development of novel selective glucocorticoid receptor mod-
ulators; compounds which maintain the therapeutically useful
anti-inﬂammatory actions of glucocorticoids, without the detri-
mental metabolic side effects. Some of these drugs are showing
promise and may soon reach the clinic.
The levelsof circulating sex steroidsdecline in later life,with loss
of the cardio-protective effects of oestrogen following menopause
in women, although whether this is reversed with hormone
replacement therapy remains controversial. This topic is coveredby
Gilliver, who has reviewed the effects of sex steroids upon immune
cell function. This is an area that will be increasingly important
to understand and exploit to our advantage as we move towards
an increasingly elderly population. Normal inﬂammatory and anti-
inﬂammatory effects of sex steroids in the human reproductive
system are reviewed by King and Critchley, who also highlight
the important role played by steroid metabolising enzymes in the
modulation of intracellular steroid access to receptors. As well as
sex steroids, levels of some other steroids also decline during later
life. DHEA and DHEAS, precursors to sex steroids, are abundant in
plasma in young adults, but decline thereafter. There is popular
interest in the use of DHEA as a supplement to counter the many
effects of aging including those associated with immune senes-
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cence, but the evidence as to whether and how it exerts these
effects has been debated. In the ﬁnal review article, Hazeldine et
al. look at the evidence regarding the immunomodulatory effects
of DHEA and DHEAS, and speculate on the mechanisms by which
these steroids may act.
The subject of this volume is large and the papers included here
by nomeans offer comprehensive coverage of the ﬁeld, but they do
give a ﬂavour of the current state of the ﬁeld and highlight exciting
and promising avenues for future research.
We would like to thank all the Authors who have contributed
manuscripts to this special issue.Wewould also like to thank all the
Reviewers who have given their time and effort to evaluating the
manuscript submissions. Last, but not least, thank you to the edito-
rial staff at Elsevier, especially Lijuan Wang and Malini Sangeneni
for keeping us on track and to time with this issue.
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